LinkedIn co-founder Reid Hoffman lashes out at Trump over reports of probe connected to E. Jean Carroll

LinkedIn co-founder Reid Hoffman has accused President Trump of political retaliation following reports that the Justice Department is examining financial contributions made by Hoffman’s nonprofit to support E. Jean Carroll’s legal battles against Trump. In an extensive post on X, Hoffman described the accusations from Trump as “absurdly false” and indicative of a broader campaign to intimidate opponents.

Hoffman’s comments came in response to a CNN report indicating that the Justice Department is investigating Carroll’s claims from 2022, in which she stated she did not receive external funding for her lawsuits, despite Hoffman’s organization providing assistance. Although the DOJ has stated it is not pursuing a criminal investigation into Carroll, it is investigating Hoffman’s nonprofit activities related to the case.

Hoffman expressed outrage over the situation, calling the premise of the investigation “laughable” and asserting that such inquiries are intended to silence dissenters. He has historically been a critic of Trump and previously attracted attention for his connections to Jeffrey Epstein, although he has not been accused of any wrongdoing related to Epstein.

E. Jean Carroll has won substantial civil judgments against Trump, totaling over $88 million, after juries found him liable for sexual abuse and defamation. Trump continues to deny Carroll’s allegations and is appealing the court decisions against him. Neither Hoffman nor Carroll has faced criminal charges, and both have declined to comment on the ongoing investigations.

Why this story matters: The case reflects ongoing tensions in U.S. politics, highlighting the intersection of legal and political battles.
Key takeaway: Hoffman’s allegations suggest concerns about the potential misuse of investigations for political purposes.
Opposing viewpoint: Supporters of Trump may view the inquiries into Hoffman as justified, questioning the legitimacy of the nonprofit’s financial support in this context.

Source link

More From Author

Malpractice Tail Coverage in the Age of Nuclear Verdicts

Replimune to resubmit melanoma drug after FDA’s Makary leaves

Leave a Reply

Your email address will not be published. Required fields are marked *